Friedreich Ataxia (FA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 

Friedreich ataxia is a rare inherited disease that causes progressive nervous system damage and movement issues. It usually starts in childhood and progresses to poor muscle coordination (Ataxia) that worsens over time. About 25% of people with Friedreich ataxia have an atypical form in which signs and symptoms begin after age 25. This condition is found in people with European, Middle Eastern, or North African ancestry. It is rarely identified in other ethnic groups. Genetically, in most cases, it is a recessively inherited disorder caused by an expansion mutation of GAA repeats in the first intron within the FXN gene, leading to a largely reduced expression of the frataxin protein. Deficiency of frataxin in cells leads to decreased activities of the mitochondrial iron-sulfur cluster–containing enzymes, accumulation of iron in the mitochondrial matrix, increased sensitivity to oxidative stress, and impaired adenosine triphosphate (ATP) production.

• The incidence of Friedreich ataxia in the USA ranges between 2.5 to 3.7 cases per 100,000 population.

Thelansis’s “Friedreich Ataxia (FA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Friedreich Ataxia (FA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Friedreich Ataxia (FA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Friedreich Ataxia (FA) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Friedreich Ataxia (FA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032